<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7344048\results\search\drug\results.xml">
  <result pre="plays a critical role in the viral replication [13]. K11777," exact="camostat" post="and EST, are cysteine protease inhibitors, which have been"/>
  <result pre="accelerate the targeted drug discovery efforts. Two HIV-1 proteinase inhibitors," exact="lopinavir" post="and ritonavir, have been considered to target SARS-CoV [17]."/>
  <result pre="âˆ’â€‰8.14 1.09 âˆ’â€‰10.82 âˆ’â€‰10.52 âˆ’â€‰0.30 âˆ’â€‰3.51 +â€‰2.68 âˆ’â€‰3.51 34.77 8" exact="Chloroquine" post="âˆ’â€‰4.95 233.3 âˆ’â€‰7.34 âˆ’â€‰6.96 âˆ’â€‰0.38 âˆ’â€‰1.34 +â€‰2.39 âˆ’â€‰1.34 30.78"/>
  <result pre="âˆ’â€‰5.77 58.47 âˆ’â€‰8.76 âˆ’â€‰8.53 âˆ’â€‰0.23 âˆ’â€‰0.68 +â€‰2.98 âˆ’â€‰0.68 30.56 10" exact="Artemisinin" post="âˆ’â€‰6.40 20.22 âˆ’â€‰6.70 âˆ’â€‰6.50 âˆ’â€‰0.20 +â€‰0.06 +â€‰0.30 +â€‰0.06 31.94"/>
  <result pre="âˆ’â€‰4.15 905.42 âˆ’â€‰4.45 âˆ’â€‰4.31 âˆ’â€‰0.14 âˆ’â€‰0.09 +â€‰0.30 âˆ’â€‰0.09 32.27 16" exact="Ritonavir" post="âˆ’â€‰7.45 3.49 âˆ’â€‰13.11 âˆ’â€‰13.15 +â€‰0.03 âˆ’â€‰3.46 +â€‰5.67 âˆ’â€‰5.67 28.61"/>
  <result pre="(grey), bilobetin (brown) and ginkgetin (white) (b) anti-malarial (chloroquine (green)," exact="hydroxychloroquine" post="(golden yellow) and artemisinin (blue) (c) anti-viral remdesivir (yellow),"/>
  <result pre="ginkgetin (white) (b) anti-malarial (chloroquine (green), hydroxychloroquine (golden yellow) and" exact="artemisinin" post="(blue) (c) anti-viral remdesivir (yellow), darunavir (blue), lopinavir (red),"/>
  <result pre="yellow) and artemisinin (blue) (c) anti-viral remdesivir (yellow), darunavir (blue)," exact="lopinavir" post="(red), galidesivir (dark pink), favipiravir (light blue), ritonavir (light"/>
  <result pre="darunavir (blue), lopinavir (red), galidesivir (dark pink), favipiravir (light blue)," exact="ritonavir" post="(light pink) and umifenovir (green) and d vitamins [vitamin"/>
  <result pre="Ser144, Cys145 7 Ginkgetin (PubChem CID:5271805) Thr26, Gly143, His163 8" exact="Chloroquine" post="(PubChem CID:2719) His41, Gly143, Cys145 9 Hydroxychloroquine (PubChem CID:3652)"/>
  <result pre="Gly143, His163 8 Chloroquine (PubChem CID:2719) His41, Gly143, Cys145 9" exact="Hydroxychloroquine" post="(PubChem CID:3652) Thr26, Asn142, Glu166 10 Artemisinin (PubChem CID:68827)"/>
  <result pre="Gly143, Cys145 9 Hydroxychloroquine (PubChem CID:3652) Thr26, Asn142, Glu166 10" exact="Artemisinin" post="(PubChem CID:68827) His41, Leu141, Asn142, Gly143, Ser144, Glu166 11"/>
  <result pre="Glu166 15 Favipiravir (PubChem CID:492405) Ser144, His163, His164, Glu166 16" exact="Ritonavir" post="(PubChem CID:392622) Thr26, His41, Cys145 17 Umifenovir (PubChem CID:131411)"/>
  <result pre="drug (red) in SARS-CoV-2 3CLpro (green) substrate binding pocket. b" exact="Artemisinin" post="drug (blue) binding mode in SARS-CoV-2 3CLpro (pink) substrate"/>
  <result pre="3CLpro (pink) substrate binding pocket. c Binding mode of the" exact="Ritonavir" post="drug (magenta) in SARS-CoV-2 3CLpro (cyan) substrate binding pocket."/>
  <result pre="the highest docking score (âˆ’â€‰6.40Â kcal/mol) as compared to O6K," exact="chloroquine" post="(-4.95Â kcal/mol) and hydroxychloroquine (âˆ’â€‰5.77Â kcal/mol) anti-malarial molecules. Importantly,"/>
  <result pre="(âˆ’â€‰6.40Â kcal/mol) as compared to O6K, chloroquine (-4.95Â kcal/mol) and" exact="hydroxychloroquine" post="(âˆ’â€‰5.77Â kcal/mol) anti-malarial molecules. Importantly, Artemisinin has demonstrated broad"/>
  <result pre="chloroquine (-4.95Â kcal/mol) and hydroxychloroquine (âˆ’â€‰5.77Â kcal/mol) anti-malarial molecules. Importantly," exact="Artemisinin" post="has demonstrated broad anti-viral activity against human cytomegalovirus, herpes"/>
  <result pre="virus, hepatitis C virus, and bovine viral diarrhea virus [47]." exact="Artemisinin" post="was shown to exhibit hydrogen bonding with His41, Leu141,"/>
  <result pre="3CLpro amino-acid residues (Fig.Â 7b). Amongst the seven antiviral drugs," exact="Ritonavir" post="showed the highest binding energy (-7.45Â kcal/mol) and lowest"/>
  <result pre="(-7.45Â kcal/mol) and lowest inhibitory constant Ki value (3.49Â ÂµM)." exact="Ritonavir" post="produced hydrogen bond interactions with Thr26, His41 and Cys145"/>
  <result pre="acids (Fig.Â 7c). A combination of two HIV-1 protease inhibitors," exact="lopinavir" post="and ritonavir, were given to critically ill SARS-CoV 2"/>
  <result pre="SARS-CoV 2 infected patients [48]. However, the combination therapy of" exact="lopinavir" post="and ritonavir was also stopped early in 13 patients"/>
  <result pre="infected patients [48]. However, the combination therapy of lopinavir and" exact="ritonavir" post="was also stopped early in 13 patients (total recruitment"/>
  <result pre="[49, 50]. Therefore, we selected vitamins, ascorbic acid (vitamin C)," exact="cholecalciferol" post="(vitamin D) and alpha-tocopherol (vitamin E) to investigate their"/>
  <result pre="Ki (âˆ’â€‰7.75Â kcal/mol and 2.08Â ÂµM respectively) as compared to" exact="vitamin C" post="and vitamin E. Amino acid residues Thr24, Thr26, His41"/>
  <result pre="signalling changes through phosphorylation changes, and here we observed that" exact="cholecalciferol" post="formed a strong hydrogen bond with Thr residues and"/>
  <result pre="antivirals are currently being used clinically in SARS-CoV-2 treatment, including" exact="lopinavir" post="[59], ritonavir [60], remdesivir [61], and oseltamivir [62]. However,"/>
  <result pre="currently being used clinically in SARS-CoV-2 treatment, including lopinavir [59]," exact="ritonavir" post="[60], remdesivir [61], and oseltamivir [62]. However, in the"/>
  <result pre="a drug-resistance event. Moreover, other classes of drugs, such as" exact="chloroquine" post="and hydroxychloroquine have shown antiviral properties by blocking viral"/>
  <result pre="event. Moreover, other classes of drugs, such as chloroquine and" exact="hydroxychloroquine" post="have shown antiviral properties by blocking viral entry into"/>
  <result pre="design of improved alpha-ketoamide inhibitorsScience202036840941232198291 17.NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of" exact="ritonavir" post="and lopinavir as SARS-CoV 3CL(pro) inhibitorsJ Theor Biol200825486186718706430 18.XueXYuHYangHXueFWuZShenWLiJZhouZDingYZhaoQet"/>
  <result pre="improved alpha-ketoamide inhibitorsScience202036840941232198291 17.NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of ritonavir and" exact="lopinavir" post="as SARS-CoV 3CL(pro) inhibitorsJ Theor Biol200825486186718706430 18.XueXYuHYangHXueFWuZShenWLiJZhouZDingYZhaoQet al.Structures of"/>
  <result pre="chemical toolboxJ Cheminform201133321982300 37.ChitranshiNDheerYKumarSGrahamSLGuptaVMolecular docking, dynamics, and pharmacology studies on" exact="bexarotene" post="as an agonist of ligand-activated transcription factors, retinoid X"/>
  <result pre="displaying SARS-CoV 3CL(pro) inhibitionBioorg Med Chem2010187940794720934345 47.EfferthTRomeroMRWolfDGStammingerTMarinJJMarschallMThe antiviral activities of" exact="artemisinin" post="and artesunateClin Infect Dis20084780481118699744 48.Cao B, Wang Y, Wen"/>
  <result pre="nsp3 in its pathogenesisJ Med Virol202092658458832083328 59.YaoTTQianJDZhuWYWangYWangGQA systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
  <result pre="Pharmacol Sci2020244572457532373997 63.ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020757 64.BasavarajappaDKGuptaVKDigheRRajalaARajalaRVPhosphorylated Grb14"/>
  <result pre="factor is involved in the regulation of glycogen synthase kinase" exact="3beta" post="(GSK3beta) signallingBiochem Biophys Res Commun201445438138625451258 66.HadfieldJMegillCBellSMHuddlestonJPotterBCallenderCSagulenkoPBedfordTNeherRANextstrain: real-time tracking of"/>
 </snippets>
</snippetsTree>
